CARGO customers in Singapore will benefit from additional capacity on IAG Cargo’s new A380 super jumbo service which is planned to operate to and from Changi International Airport later this year.
IAG Cargo, the merged freight business of British Airways and Iberia, believes the new aircraft will prove particularly beneficial to the burgeoning pharmaceuticals sector, as its fully air-conditioned hold makes the aircraft ideally suited to Constant Climate, the carrier’s precision temperature-control product.
John Cheetham, regional commercial manager for the Asia Pacific and India region at IAG Cargo, comments: “Our ability to offer temperature control capabilities between Singapore, Heathrow and beyond is a real competitive advantage.
“For customers in Singapore’s important pharmaceuticals market, IAG Cargo can now offer unrivalled quality through each and every step of the air cargo journey,” he insists.
The pharmaceuticals market in Singapore has benefited from high levels of investment and the government’s increased commitment to healthcare in the region.
More than 30 of the world’s leading biomedical sciences companies (including GlaxoSmithKline, Novartis and Takeda) have set up operations on the island, helping to establish it as an important global research and development hub.
The new A380 service is the latest in a series of initiatives from IAG Cargo to leverage this market opportunity.
Having appointed Singapore-based Shiv Sivaraman as its new Constant Climate manager for Asia Pacific, IAG Cargo customers will also benefit from new dnata ground handling facilities, which offer a precision temperature-controlled environment for loose and intact cargo.
